Moldvay Judit
Semmelweis Egyetem, Általános Orvostudományi Kar Pulmonológiai Klinika, Budapest.
Orv Hetil. 2012 Jun 10;153(23):909-16. doi: 10.1556/OH.2012.29397.
Molecular targeted treatment, with broadening opportunities, plays an important role in the management of lung cancer patients, which renders molecular mapping of the tumor tissue crucial. In case of cytotoxic chemotherapy, there is no patient selection according to tissue biomarkers; however, there are expanding results that might help oncologists to use personalized chemotherapy in the near future. This may be of great importance when patients' age, performance status and/or co-morbidity make the applicability of chemotherapy uncertain. Nowadays, molecular targeted treatment gives hope mainly for patients with adenocarcinoma; however, promising therapeutic targets have already been outlined due to intensive research. In these days, we are experiencing a turbulent era of onco-pulmonology, which - despite all difficulties - gives hope for both patients and clinicians.
随着机会不断增加，分子靶向治疗在肺癌患者的管理中发挥着重要作用，这使得肿瘤组织的分子图谱绘制至关重要。在细胞毒性化疗中，不会根据组织生物标志物进行患者选择；然而，越来越多的研究结果可能有助于肿瘤学家在不久的将来使用个性化化疗。当患者的年龄、身体状况和/或合并症使化疗的适用性不确定时，这可能非常重要。如今，分子靶向治疗主要给腺癌患者带来希望；然而，由于深入研究，已经勾勒出了有前景的治疗靶点。如今，我们正经历着肿瘤肺科学的动荡时代，尽管困难重重，但它给患者和临床医生都带来了希望。
